 |
|
“The availability of the TAXUS system will
positively impact patients’ lives, meaning they
will not have a recurrence of angina, they will not need to undergo
repeat angiograms, angioplasties or cardiac surgery in the future.
The TAXUS system truly will increase the quality of their lives
and increase the general health of society as a whole.”

|
|

Gregg W. Stone, M.D., TAXUS IV Clinical
Trial Principal Investigator and Vice Chairman of The Cardiovascular
Research Foundation at the Lenox Hill Heart and Vascular Institute,
New York.
|
|
 |
 |